8-K: Theriva Biologics Implements 1-for-25 Reverse Stock Split to Meet NYSE American Listing Requirements

Theriva Biologics has completed a 1-for-25 reverse stock split to comply with NYSE American listing standards, effective August 26, 2024.

Summary

• Theriva Biologics has enacted a 1-for-25 reverse stock split of its common stock.
• The reverse stock split was approved by the Board of Directors on August 15, 2024.
• A Certificate of Change was filed with the State of Nevada on August 22, 2024, to effect the split.
• The reverse stock split became effective on August 26, 2024, at 12:01 a.m. Eastern Time.
• Trading on a post-split basis commenced on the NYSE American when the market opened on August 26, 2024.
• The number of outstanding shares was reduced from 25,131,230 to 1,005,249, subject to rounding.
• No fractional shares were issued; instead, shareholders received an additional fractional share to round up to the next whole number.
• The reverse stock split was implemented to meet the per share price requirements of the NYSE American.
• The company's transfer agent, Equiniti Trust Company, is managing the exchange process.
• The reverse stock split did not change the par value of the common stock or modify voting rights.
• Adjustments were made to outstanding preferred stock, stock options, and warrants.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a necessary corporate action to maintain listing compliance. While not inherently positive, it is a standard procedure in such situations.

Positives

• The reverse stock split ensures continued compliance with NYSE American listing requirements.
• The company has taken steps to avoid fractional shares, simplifying the process for shareholders.
• The reverse stock split did not alter the par value of the common stock or modify voting rights.

Negatives

• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
• The reverse stock split was necessary to maintain listing compliance, indicating potential past share price weakness.

Risks

• The reverse stock split may not be sufficient to maintain long-term compliance with NYSE American listing requirements if the share price does not improve.
• The reduction in outstanding shares could potentially increase volatility in the stock price.

Future Outlook

The company will continue to trade on the NYSE American under the symbol TOVX with a new CUSIP number.

Management Comments

• The Board of Directors approved the reverse stock split to meet the per share price requirements of the NYSE American.

Industry Context

Reverse stock splits are a common mechanism for companies to regain compliance with exchange listing requirements when their stock price falls below a certain threshold. This action is often seen in the biotechnology sector where stock prices can be volatile.

Comparison to Industry Standards

• Reverse stock splits are a common practice for companies facing delisting from major exchanges, particularly in the biotech sector.
• Many companies in similar situations have implemented reverse stock splits to maintain their listing status, such as Agenus Inc. (AGEN) which recently completed a 1-for-10 reverse stock split.
• The 1-for-25 ratio is within the range of reverse stock splits seen in the industry, which can vary from 1-for-2 to 1-for-50 or more.
• The primary goal is to increase the per-share price to meet minimum listing requirements, which is a common challenge for companies with low-priced stocks.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively unchanged immediately after the split.
• The company's ability to remain listed on the NYSE American is maintained, which is beneficial for shareholders.

Next Steps

• The company's common stock will continue to trade on the NYSE American under the symbol TOVX with the new CUSIP number 87164U 508.
• Shareholders holding shares in brokerage accounts will see the adjustment automatically reflected in their accounts.

Key Dates

Keywords

reverse stock split, NYSE American, stock split, share price, listing compliance, Theriva Biologics, TOVX, common stock